Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rosiglitazone × 90 days × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡